‘Development of hypoxia-activated quadruplex DNA binders as potential cancer therapeutics’

Project description

Smart drugs against cancer

Many chemotherapy regimens such as cisplatin target DNA, causing non-specific side effects in normal cells. Therefore, there is a pressing need for new, more specific and effective anti-cancer drugs. The EU-funded G4Redox project addresses this problem by developing compounds that leave double-stranded DNA intact and target transient G-quadruplex DNA structures that form during replication and transcription. Moreover, these drugs become activated only in the presence of low oxygen levels such as in the case of the tumour microenvironment. Researchers envision combining these drugs with other anti-cancer pharmaceuticals for a synergistic effect.

Fields of science

• natural sciences › biological sciences › genetics › DNA
• medical and health sciences › clinical medicine › oncology
• medical and health sciences › basic medicine › pharmacology and pharmacy › drug resistance

Programme(s)

• H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme
• H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility

Topic(s)

• MSCA-IF-2020 - Individual Fellowships

Call for proposal

H2020-MSCA-IF-2020

See other projects for this call

Funding Scheme

MSCA-IF-EF-ST - Standard EF

Coordinator

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE

Net EU contribution

€ 224 933,76

Address

South Kensington Campus Exhibition Road
SW7 2AZ London
United Kingdom

Activity type

Higher or Secondary Education Establishments

Non-EU contribution

€ 0,00

Region

London › Inner London — West › Westminster